# Role of Hematopoietic System and Proteomics in HIV-Associated Cardiovascular Disease

> **NIH NIH K24** · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · 2021 · $193,512

## Abstract

Project Summary/Abstract
Dr. Hsue is one of the few cardiologists in the world with both extensive research and clinical expertise in HIV
and has devoted the last 15 years studying cardiovascular disease (CVD) in the setting of HIV. The initial part
of her career was spent 1) establishing a HIV Cardiology Clinic at Zuckerberg San Francisco General (ZSFG),
2) developing the infrastructure to perform patient oriented research in Cardiology including development of a
vascular laboratory for clinical research, 3) performing studies that evaluate the mechanisms underlying HIV
infection and CVD and 4); leading clinical trials aimed to reducing inflammation and CVD risk in HIV. The
findings from her work have shown that 1) HIV infection is independently associated with CVD, independent of
traditional risk factors or ART and 2) chronic inflammation in the setting of effectively treated HIV infection
underlies this increased CV risk. Initial K24 support has led to a significant increase in the number of mentees,
grants, and publications for Dr. Hsue and new research directions including use of novel imaging to assess
HIV disease burden and identification of therapies to reduce HIV-associated inflammation and CV risk. For the
K24 renewal period, her career goals are to perform cutting edge clinical/translational studies and mentoring
that will lead to improvements in treating, identifying and preventing CVD among PLWH and also impact other
comorbidities and HIV cure. Dr. Hsue plans to 1) expand her research to include the role of somatic mutations
in the hematopoietic system (termed clonal hematopoiesis of indeterminate potential, CHIP) and proteomics in
HIV-associated CVD; 2) continue her time spent mentoring junior investigators in the fields of HIV infection,
inflammation, and CVD with a focus on transition to full-independence; 3) obtain leadership training to build
clinical and translational research programs that can be used by mentees and will make her a better mentor.
The majority of Dr. Hsue's career development will occur at UCSF which offers outstanding resources for
clinical/translational research, basic science, imaging, HIV, and mentoring/leadership training. Her K24
proposal will extend upon her current NIH-funded investigations by studying the underlying mechanism of HIV-
associated atherosclerosis in treated HIV with the following Specific Aims: Aim 1A: To determine if clonal
hematopoiesis of indeterminate potential (CHIP) mutations are more prevalent in peripheral blood cells of
PLWH vs. uninfected controls; Aim 1B: To determine whether the presence of CHIP mutations are associated
with increased arterial inflammation and metabolic activity of the hematopoietic system as assessed by FDG-
PET/CT; Aim 2A: To identify a unique proteomic signature in PLWH that is associated with arterial
inflammation and metabolic activity of the hematopoietic system, and Aim 2B: to characterize changes in
proteins and biological pathways that are altered aft...

## Key facts

- **NIH application ID:** 10130430
- **Project number:** 5K24AI112393-07
- **Recipient organization:** UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
- **Principal Investigator:** Priscilla Y. Hsue
- **Activity code:** K24 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $193,512
- **Award type:** 5
- **Project period:** 2014-03-01 → 2025-02-28

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10130430

## Citation

> US National Institutes of Health, RePORTER application 10130430, Role of Hematopoietic System and Proteomics in HIV-Associated Cardiovascular Disease (5K24AI112393-07). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10130430. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*